Passage BIO Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · · (Unaudited) · · · | ||||||
| (in thousands, except share and per share data) · March 31, 2025 · December 31, 2024 | ||||||
| Assets · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $63,357 | | $37,573 | ||
| Marketable securities | | | — | | | 39,183 |
| Prepaid expenses and other current assets | | 2,121 | | 838 | ||
| Prepaid research and development | | 1,191 | | 1,221 | ||
| Total current assets | | 66,669 | | 78,815 | ||
| Property and equipment, net | | 5,523 | | 9,331 | ||
| Right of use assets - operating leases | | | 13,540 | | 13,803 | |
| Other assets | | 274 | | 463 | ||
| Total assets | | $86,006 | | $102,412 | ||
| Liabilities and stockholders’ equity | | | | |||
| Current liabilities: | | | | |||
| Accounts payable | | $1,458 | | $742 | ||
| Accrued expenses and other current liabilities | | 3,994 | | 6,707 | ||
| Non-refundable sublicense and transition services payments received | | | 8,732 | | | 8,226 |
| Operating lease liabilities | | | 3,641 | | 3,688 | |
| Total current liabilities | | 17,825 | | 19,363 | ||
| Operating lease liabilities - noncurrent | | 21,475 | | 21,788 | ||
| Total liabilities | | 39,300 | | 41,151 | ||
| | | | | | | |
| Commitments and contingencies (note 11) | | | | |||
| | | | | | | |
| Stockholders’ equity: | | | | |||
| Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both March 31, 2025 and December 31, 2024 | | | — | | | — |
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 62,148,274 shares issued and outstanding at March 31, 2025 and 62,061,774 shares issued and outstanding at December 31, 2024 | | 6 | | 6 | ||
| Additional paid‑in capital | | 721,340 | | 720,482 | ||
| Accumulated other comprehensive income (loss) | | | — | | | 8 |
| Accumulated deficit | | (674,640) | | (659,235) | ||
| Total stockholders’ equity | | 46,706 | | 61,261 | ||
| Total liabilities and stockholders’ equity | | $86,006 | | $102,412 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.